One of the problems of having a PSA that is elevated but less than 10 mg/ml is the probability of detecting prostate cancer. After we have determined you have an elevated PSA, usually a prostate biopsy is recommended. In those men with a PSA less than 10, there is a 1 in 6 chance that prostate

Recently reported data from  the National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) demonstrate that approximately 90% of patients, regardless of race, were diagnosed with localized prostate cancer between 1995 and 2000. Currently, in the Las Vegas area, I have

Clinically insignificant cancer is a indolent, slow growing disease in many patients and may not pose a threat during a patient’s lifetime.

 

The challenge is to identify those patients who are not likely to experience significant progression.

These are some of the parameters I consider in the

The prostate biopsy is the standard of care for the initial diagnosis of prostate cancer. This pertains to men with significant PSA changes and/or suspicious digital rectal examination. However, up to 30% of the performed transrectal ultrasound guided biopsies are negative despite a persistent

I have been using cryotherapy of the prostate more in my practice. For the patient population that is suited for this therapy it is a great option. We are achieving great continence rates and moderate success on potency rates. Although it is too early to tell, if this trend continues I should meet

PCA3 is a new prostate-specific gene that is highly over-expressed in prostate cancer. Specifically it is a nucleic acid amplification assay detecting  in the urine the expression of PSA RNA as a marker of prostate cells and PCA3 RNA which is selectively expressed in the majority of prostate

Screening for Prostate Cancer

 

How do you effectively screen for the most common cancer in American men and keep costs reasonable? Also, realize that many men will get prostate cancer (~16%) but few will die from the disease.

 

In general, most urologists recommend screening if life expectancy is

I have been thinking of changing around some of my recommendations I give to my patients regarding prostate cancer prevention.

 

There are 4 groups of patients that I am concerned with.

1. Patients with a rising PSA and negative biopsies

2. Patients treated either with a radical prostatectomy or